Carvedilol more effective than non selective beta blockers in reducing portal hypertension
Portal hypertension (PH) is characterized by elevated pressure in portal venous system. The most common cause of portal hypertension is cirrhosis (scarring) of the liver. The PH treatments in patients with compensated cirrhosis is to reduce the risk of hepatic decompensation.
Carvedilol is popularly used to treat high blood pressure and heart failure. It is also used after a heart attack to improve the chance of survival in case if the heart is not pumping well. Several studies are tested to control hepatic blood pressure in patients.
Laura Turco and team summarized in the review the evidence behind Baveno-VII recommendations on the use of carvedilol in patients with cirrhosis.
Carvedilol non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance has shown superior efficacy than traditional NSBBs in lowering PH in patients with cirrhosis and may be, therefore, the NSBB of choice for the treatment of clinically significant portal hypertension reveals a review in Liver International journal.
The key findings of the study are
• In primary prophylaxis of variceal bleeding, carvedilol has been demonstrated to be more effective than endoscopic variceal ligation (EVL).
• In patients with compensated cirrhosis carvedilol achieves higher rate of hemodynamic response than propranolol, resulting in a decreased risk of hepatic decompensation.
• In secondary prophylaxis, the combination of EVL with carvedilol may prevent rebleeding and non-bleeding further decompensation better than that with propranolol.
• In patients with ascites and gastroesophageal varices, carvedilol is safe and may improve survival, as long as no impairment of the systemic hemodynamic or renal dysfunction occurs, with maintained arterial blood pressure as suitable safety surrogate. The target dose of carvedilol to treat PH should be 12.5 mg/day.
In conclusion, Carvedilol is the most potent NSBB in terms of portal pressure reduction and is, therefore, the recommended NSBB for both stages of the disease at the maximum dose of 12.5 mg/day (6.25 mg/bid). In patients with cirrhosis, lowering portal pressure by NSBBs is associated with a clear reduction in the risk of first and further decompensation and ultimately improves survival both in compensated and decompensated patients ended the researchers.
Reference: Reference: Laura Turco, Thomas Reiberger, Giovanni Vitale, Vincenzo La Mura; Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension; DOI: https://doi.org/10.1111/liv.15559
